Validation of DNA Methylation Markers for Universal and Site-specific Guided Cancer Detection, VANGUARD Study

NCT06304168 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 6150

Last updated 2026-03-03

No results posted yet for this study

Summary

This study explores the potential value of a new blood test approach for early detection of cancer.

Conditions

  • Hematopoietic and Lymphatic System Neoplasm
  • Malignant Solid Neoplasm

Interventions

OTHER

Non-Interventional Study

Non-interventional study

Sponsors & Collaborators

Principal Investigators

  • John B. Kisiel, M.D. · Mayo Clinic in Rochester

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-05-13
Primary Completion
2028-05-15
Completion
2028-05-15

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06304168 on ClinicalTrials.gov